Theriva Biologics Inc surges amid market decline
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 29 Dec 25
Source: 8-K
Theriva Biologics Inc (TOVX) saw a significant price increase of 18.98% in pre-market trading, as the stock crossed above its 5-day SMA.
This surge comes amid broader market weakness, with the Nasdaq-100 down 0.46% and the S&P 500 down 0.09%. The stock's resilience suggests sector rotation as investors shift focus to biotech companies.
The movement indicates a potential shift in investor sentiment towards Theriva Biologics, highlighting its strong position in the current market environment.
Analyst Views on TOVX
About TOVX
Theriva Biologics, Inc. is a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. The Company is advancing a new oncolytic adenovirus platform. The Company’s candidates are VCN-01, SYN-004 (ribaxamase) and SYN-020. VCN-01, an oncolytic adenovirus designed to replicate selectively and aggressively within tumor cells, and to degrade the tumor stroma barrier that serves as a physical and immunosuppressive barrier to cancer treatment; SYN-004 (ribaxamase) which is designed to degrade certain commonly used IV beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent microbiome damage, thereby limiting overgrowth of pathogenic organisms such as VRE (vancomycin resistant Enterococci), and SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) produced under cGMP conditions and intended to treat both local GI and systemic diseases.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
